Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD
– License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular degeneration.– OliX to receive an upfront payment…